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Aims The effect of statins on risk of heart failure (HF) hospitalization and HF death remains uncertain. We aimed to establish
whether statins reduce major HF events.
Methods
and results
We searched Medline, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized controlled endpoint
statin trials from 1994 to 2014. Collaborating trialists provided unpublished data from adverse event reports. We included
primary- and secondary-prevention statin trials with .1000 participants followed for .1 year. Outcomes consisted of first
non-fatal HF hospitalization, HF death and a composite of first non-fatal HF hospitalization or HF death. HF events occurring
,30 days after within-trial myocardial infarction (MI) were excluded. We calculated risk ratios (RR) with fixed-effects meta-
analyses. In up to 17 trials with 132 538 participants conducted over 4.3 [weighted standard deviation (SD) 1.4] years, statin
therapy reduced LDL-cholesterol by 0.97 mmol/L (weighted SD 0.38 mmol/L). Statins reduced the numbers of patients
experiencing non-fatal HF hospitalization (1344/66 238 vs. 1498/66 330; RR 0.90, 95% confidence interval, CI 0.84–0.97) and
the composite HF outcome (1234/57 734 vs. 1344/57 836; RR 0.92, 95% CI 0.85–0.99) but not HF death (213/57 734 vs. 220/
57 836;RR0.97,95%CI0.80–1.17).Theeffectofstatinsonfirstnon-fatalHFhospitalizationwassimilarwhetherthiswaspreceded
by MI (RR 0.87, 95% CI 0.68–1.11) or not (RR 0.91, 95% CI 0.84–0.98).
Conclusion Inprimary-andsecondary-preventiontrials, statinsmodestlyreducedtherisksofnon-fatalHFhospitalizationandacompositeofnon-
fatal HF hospitalization and HF death with no demonstrable difference in risk reduction between those who suffered an MI or not.
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Introduction
Heart failure (HF) is a condition characterized by debilitating symp-
toms, a particularly poor quality of life, frequent hospital admissions
and reduced survival.1 It also places a major economic burden on
healthcare systems. Consequently, therapies which reduce the risk
of developing HF are highly desirable and likely to be cost effective.
Coronary heart disease is reported to be the most common cause
of HF.2 Statin therapy has been conclusively shown to reduce the
risk of myocardial infarction (MI) in primary- and secondary-
prevention populations.3 By reducing first and recurrent injurious
myocardial events, statin therapy should reduce the development
ofHF. It is also possible that statin therapymay influence the develop-
ment of HF by other mechanisms.
To date, about half of the major placebo- and standard care-
controlled statin endpoint trials have published data on a variety of
HF outcomes and a borderline reduction in HF hospitalization or
HF death was only shown in one trial.4–11 Data regarding HF hospi-
talization from four dose-comparison trials have been pooled with
the overall result suggesting that intensive statin therapy reduces
HF hospitalization compared with moderate dose therapy.12
However, the types of HF endpoints have varied somewhat with
some trials reporting any HF adverse event, some reporting HF
death, some reporting non-fatalHFhospitalization, and some report-
ing a composite of fatal and non-fatalHFevents. This heterogeneity in
the categories ofHFoutcomes collected, alongwithmissing informa-
tion, has precluded a comprehensive pooling of HF data. In addition,
noneof the existing reports describedwhether any effect onHF hos-
pitalization might be fully explained by preventing precursor MIs.
The purpose of this analysis was to obtain comprehensive and har-
monized data for major HF events (non-fatal hospitalization, death,
and a composite of both) in major statin trials for the purpose of
evaluating whether, and if so to what extent, statin therapy may
reduce major HF events. In addition, we wished to explore
whether any reduction in HF was primarily driven by a reduction in
non-fatal MI.
Methods
Data sources and searches
We collected data from major randomized controlled trials designed to
assess the effect of statins on cardiovascular outcomes. We searched
Medline, Embase, and the Cochrane Central Register of Controlled
Trials with the terms ‘statin’ and ‘HMGCoA reductase inhibitor’, plus in-
dividual statin names as title or keywords, on 25th March 2014.
Study selection
We limited the search to trials of adults, published in the English language,
between 1 January 1994 and 1 January 2014. We included placebo con-
trolled, standard care-controlled, and intensive vs. moderate dose
trials in primary prevention, secondary-prevention, and mixed primary-
and secondary-prevention populations. We excluded trials conducted
entirely in participants with HF, dialysis, or organ transplant populations,
those with ,1000 enrolled participants, trials with a mean follow-up of
,1 year, trials of combination therapy, and trials assessing surrogate
markers of cardiovascular disease. Study protocol and data request
sheets were sent to investigators from the relevant trials as described
below to collect unpublished data (Supplementary material online,
Appendix). A specific definition ofHFeventswas not provided to the con-
tributing investigators.
Data extraction and quality assessment
Two researchers (R.C. and D.P.) independently reviewed abstracts and
manuscripts to identify relevant trials. A third reader (J.J.M.) resolved any
discrepancies. An assessment of study design and quality for each trial
wasmadeusing the Jadad score.13Our search strategy identified23poten-
tially suitable trials for which unpublished data were sought6–11,14–30
(Figure 1). The study was conducted according to published Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guidelines.31
Unpublished tabular datawere collected regarding the numbers of parti-
cipants who experienced a non-fatal hospitalization for HF, the number
that died due to HF, and the number that suffered either a non-fatal HF
hospitalization or HF death (composite HF outcome) in each arm. Inves-
tigators were asked to detail the number of participants with HF at ran-
domization in both treatment arms (where available), LDL-cholesterol
levels at randomization and 1 year, and the number of participants who
suffered a within-trial non-fatal MI. Numbers with incident HF events
were also requested separately in only those participants without HF
at baseline. Heart failure events occurring ,30 days after within-trial
MI were specifically excluded fromunpublished data sought from collab-
orating trials. This decision was driven by the following considerations:
events within 30 days of MI would have been variably recorded as
many participants would still have been in hospital due to the index MI
(i.e. some events would still not be captured by assessing HF hospitaliza-
tion); development of HF soon after MI may be transient, reflecting
cardiac stunning, andmay not necessarily lead to chronic HF; and if parti-
cipants developed clinically significant HF they may well have suffered a
subsequent HF hospitalization in the trial anyway. Of the 23 trials, 17
trials7–11,15,16,18,20,21,24–30 were able to provide unpublished HF data,
with HF events occurring ,30 days after within-trial MI excluded.
These results were analysed for the main HF analyses. For the remaining
six trials, HF outcomes were available from four trials (three with
published data;6,14,23 one with unpublished data17). Data regarding
timing of incident cases of HF with regard to within-trial (i.e. post-
randomization) MI were not available in these four trials with the result
that HF events within 30 days of MI could not be excluded and their
results were therefore only combined with the full dataset in sensitivity
analyses. Two authors (D.P. and R.C.) independently abstracted and
tabulated information about the number of participants without HF at
baseline and incident cases of HF according to randomization group in
those trials where only published data were available.
Data synthesis and analysis
To identify potential relationships of statins with the risk of developing
HF, we calculated risk ratios (RRs) as the ratio of cumulative incidence
and 95% confidence intervals (CIs) from the available data for all trial par-
ticipants at baseline and for those who experienced an HF event during
trial follow-up. Study-specific RRs were pooled using fixed-effects
model meta-analysis. Statistical heterogeneity across studies was quanti-
fied using the I2 statistic, with P. 0.10 considered statistically non-
significant. The I2 statistic is derived from the Q statistic ([Q2 df/Q] ×
100) and provides ameasureof the proportion of the overall variation at-
tributable to between-study heterogeneity.We also separately analysed
the risk of HF events depending on whether a participant had or had not
suffered a preceding within-trial MI. However, the available data did not
allow a formal statistical comparison of those who had and had not suf-
fered a preceding within-trial MI.
Placebo- and standard care-controlled statin trials as well as dose-
comparison statin trials were combined in all analyses though their re-
spective pooled results were also compared by fixed-effect inverse-
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Figure1 Flowdiagramof literature search to identify randomized placebo-controlled trials, standard care-controlled trials, anddose-comparison
statin trials.
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variance modelling in a sensitivity analysis. Additional sensitivity analyses
included random effects meta-analysis of non-fatal HF hospitalization, a
comparison of trial populations (primary prevention, secondary preven-
tion, andmixed population), a comparisonof trialswhich had and had not
pre-specified any HF outcome, an analysis limited to only those trials
which could provide data on participants without HF at baseline, and
an analysis which added HF events from four trials (including events
within 30 days of within-trial MI6,14,17,23) to the unpublished trial data
already analysed in themain analyses.We assessed the potential for pub-
lication bias through formal statistical testing, namely funnel plots and
Egger tests.32 To evaluate potential relationships of the effects of
statins on non-fatal MI and LDL-cholesterol reductions, respectively,
with occurrence of HF events, meta-regression analyses were per-
formed.
All P-valueswere two sided, and P-valueof,0.05was considered stat-
istically significant for the meta-analyses and meta-regression analyses.
Analyses were conducted using Stata/SE 13 (StataCorp).
Results
In the main analyses, we included unpublished data from up to 132
568 participants (average age 63 years, 29% women) from 17 trials
who were followed up for 4.3 (weighted SD 1.4) years on average.
These participants included a small proportionwith symptomatically
mild HF at baseline (weighted mean 2.8% of participants, range
0–16.1% in 13 trials with available data). Baseline characteristics
are provided in Table 1. At 1 year, LDL-cholesterol was reduced by
a weighted mean of 0.97 mmol/L (weighted SD 0.38 mmol/L).
Trials were generally of high quality with a median Jadad score of 5
(range 3–5).
Effect of statin therapy on non-fatal
myocardial infarction
In 16 trials (one trial not able to provide data on non-fatal MI), risk of
non-fatal myocardial MI was reduced by 26% on statin therapy (2287
first events in 65 438 participants on statin vs. 3107 first events in 65
530 on control; RR 0.74, 95% CI 0.70–0.78).
Effect of statin therapy on heart failure
outcomes
First non-fatal HF hospitalization was reduced by 10% on statins
(1344/66 238 vs. 1498/66 330 first events; RR 0.90, 95% CI 0.84–
0.97) in 17 trials (Figure 2A). This equates to numbers needed to
treat of 1454 (non-significant) in the primary prevention trials, 552
(non-significant) in the mixed trials and 200 (95% CI 126–574) in
the secondary-prevention trials over 5 years to prevent one
patient experiencing a first non-fatal HF hospitalization when the
overall control-arm risks of events were 1.2, 7.1, and 7.0 per
1000 patient-years, respectively. Heart failure death was not
reduced by statin therapy in 14 trials (213/57 734 vs. 220/57 836
events; RR 0.97, 95% CI 0.80–1.17) (Figure 2B). The risk of a partici-
pant suffering a first composite HF outcome (death or non-fatal hos-
pitalization)was reducedby 8%on statin therapy in 14 trials (1234/57
734 vs. 1344/57 836 first events; RR 0.92, 95% CI 0.85–0.99)
(Figure 2C). There was little statistical evidence of heterogeneity for
all these analyses (I2 0%) and therewas no statistical evidence of pub-
lication bias (Figure 3).
In meta-regression analyses, no relationship was observed
between either non-fatal MI reduction (P ¼ 0.69; Supplementary
material online, Figure S1) or absolute LDL-cholesterol reduction
achieved at 1 year (P ¼ 0.75; Supplementary material online, Figure
S2) on statins, and risk of first non-fatal HF hospitalisation. Results
were similar when the relationships between these two variables
were compared with risk of the composite HF outcome (P ¼ 0.18
and P ¼ 0.18, respectively).
Of the17 trials included in themainHFanalyses, 13 trialswere able
to provide data on HF status at baseline. Analyses in the 90 001
(97.2% of total) participants without documented HF at baseline in
these 13 trials generally produced similar results to themain analyses
described above (Supplementary material online, Table S1) although
with fewerevents available forpooling andconsequent lossof power,
the benefit of statin therapy over control therapy did not reach stat-
istical significance.
Influence of statin therapy on risk of heart
failure events preceded or not preceded by
myocardial infarction
Only 10–15%of first compositeHFoutcomes aswell as non-fatalHF
hospitalizations were preceded by a documented within-trial non-
fatal MI (this excludes all HF events within 30 days of MI). There
was no demonstrable difference between the effect of statin
therapy on risk of a first HF event preceded by a within-trial MI or
not (Table 2). For non-fatal hospitalization, RRs were 0.87 (95% CI
0.68–1.11) and 0.91 (95% CI 0.84–0.98) while for the composite
HF outcome RRs were 0.86 (95% CI 0.68–1.09) and 0.94 (95% CI
0.86–1.01), respectively.
Sensitivity analyses
Therewas no evidence of any difference in the effect of statin therapy
on HF events in primary prevention, secondary prevention, and
mixed trial populations (P ¼ 0.42; Supplementary material online,
Figure S3). Similarly, no difference was demonstrated between
placebo/standard care-controlled trials and dose-comparison trials
(P ¼ 0.23; Supplementary material online, Figure S4). We tested
whether there was any heterogeneity between trials which did or
did not pre-specify any HF event as a secondary or tertiary
outcome and, again, no difference was found (P ¼ 0.62; Supplemen-
tary material online, Figure S5). When random effects meta-analysis
was employed for non-fatal HF hospitalization, results were identical
to those obtained from fixed-effect meta-analysis, namely RR 0.90
(95% CI 0.84–0.97).
The analyses were repeated with the inclusion of data from the
four trials (additional 24 560 participants) which did not report
timing of within-trial MI. Results were similar to the main analyses
(Supplementary material online, Table S2).
Discussion
This study demonstrates that statin therapy led to reductions in the
number of patients suffering HF events in major primary- and
secondary-prevention trials over 4 years of follow-up. The risks
of both non-fatal hospitalization and the composite HF outcome
(non-fatal HF hospitalization or HF death) were reduced by 10%,
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Table 1 Baseline characteristics for 21 statin trials providing data on heart failure events
Trial Year Trial
population
Active arm (n) Control arm (n) Age
(years)
LDL-c
(mmol/L)
Follow-up
(years)
Women (%) Percentage with
HF at baseline (%)
Was HF a
pre-specified
endpoint?
Included in
main HF
analyses
4S5,14 1994 Secondary Simvastatin 10–40 mg (2221) Placebo (2223) 58.5 (2) 4.87 (0.66) 5.4 (2)* 19 – No No
WOSCOPS15 1995 Primary Pravastatin 40 mg (3302) Placebo (3293) 55.2 (5.5) 4.96 (0.45) 4.81 (0.78) 0 0.0 No Yes
CARE16 1996 Secondary Pravastatin 40 mg (2081) Placebo (2078) 58.6 (9.3) 3.59 (0.38) 4.83 (0.94) 14 7.2 Yes Yes
AFCAPS TEXCAPS17 1998 Primary Lovastatin 20–40 mg (3304) Placebo (3301) 58 (7) 3.89 (0.43) 5.2 (0.9) 15 0.0 Yes No
LIPID6 1998 Secondary Pravastatin 40 mg (4512) Placebo (4502) 62 (2)* 3.88 (3.36–4.40)* 6.1 (2) 17 – Yes No
GISSI PREVENZIONE18 2000 Secondary Pravastatin 20 mg (2138) No treatment (2133) 59.9 (10.4) 3.92 (0.67) 1.9 (0.6) 14 16.1 No Yes
HPS20 2002 Mixed Simvastatin 40 mg (10 269) Placebo (10 267) 64 (8.4) 3.38 (0.83) 5 (1.1) 25 – No Yes
PROSPER7 2002 Mixed Pravastatin 40 mg (2891) Placebo (2913) 75.3 (3.4) 3.79 (0.80) 3.2 (0.63) 52 – Yes Yes
GREACE8 2002 Secondary Atorvastatin 10–80 mg (800) Usual care (800) 59 (12) 4.65 (0.62) 3 (1) 22 – Yes Yes
ALLHAT-LLT9 2002 Mixed Pravastatin 40 mg (5170) Usual care (5185) 66.6 (7.6) 3.76 (0.55) 4.8 (1.3) 49 0.0 Yes Yes
ASCOT-LLA10 2003 Primary Atorvastatin 10 mg (5134) Placebo (5106) 62.7 (8.5) 3.44 (0.72) 3.2 (0.6) 19 0.0 Yes Yes
CARDS21 2004 Primary Atorvastatin 10 mg (1428) Placebo (1410) 61.6 (8.1) 3.03 (0.71) 3.84 (1.06) 32 0.1 No Yes
ALLIANCE11 2004 Secondary Atorvastatin 10–80 mg (1217) Usual care (1225) 61.2 (8.8) 3.80 (0.68) 4.29 (1.5) 18 6.8 Yes Yes
A TO Z23 2004 Secondary Simvastatin 40–80 mg (2265) Placebo + Simvastatin 20 mg
(2232)
61 (53–69)* 2.87 (2.46–3.39)* 2.0 (2)* 24 – Yes No
TNT24 2005 Secondary Atorvastatin 80 mg (4995) Atorvastatin 10 mg (5006) 61 (8.8) 2.52 (0.45) 4.9 (0.76) 19 7.8 Yes Yes
IDEAL25 2005 Secondary Atorvastatin 80 mg (4439) Simvastatin 20–40 mg (4449) 61.7 (9.5) 3.14 (0.90) 4.62 (0.82) 19 6.0 Yes Yes
ASPEN26 2006 Mixed Atorvastatin 10 mg (1211) Placebo (1199) 61 (8.2) 2.93 (0.66) 4 (0.55) 34 0.4 Yes Yes
MEGA27 2006 Primary Pravastatin 10–20 mg (3866) Usual care (3966) 58.3 (7.2) 4.05 (0.45) 5.29 (1.92) 68 0.1 No Yes
SPARCL28 2006 Primary Atorvastatin 80 mg (2365) Placebo (2366) 62.8 (11.3) 3.45 (0.62) 4.8 (1.1) 40 0.4 Yes Yes
JUPITER29 2008 Primary Rosuvastatin 20 mg (8901) Placebo (8901) 66.1 (7.7) 2.70 (0.48) 2.1 (0.9) 38 0.3 No Yes
SEARCH30 2010 Secondary Simvastatin 80 mg (6031) Simvastatin 20 mg (6033) 64.2 (8.9) 2.50 (0.61) 6.7 (1.5) 17 – No Yes
HF, heart failure; LDL-c, low-density lipoprotein cholesterol.
Data are listed as mean (SD) or *median (interquartile range).
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Figure2 Theeffectof statin therapyon the riskof (A) first non-fatal heart failurehospitalization in17 trials (B) heart failuredeath in 14 trials (C) first
composite heart failure outcome in 14 trials. All heart failure events within 30 days of myocardial infarction were excluded.
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drivenby a reduction in non-fatal hospitalization. Thismodest benefit
appeared similar in those with and without a history of coronary
heart disease atbaseline, and acrossbothplacebo- and standard care-
controlled trials, as well as dose-comparison trials. In contrast, no re-
duction inHF deathwas noted though therewere fewer events and a
small treatment benefit cannot be excluded. While relative risk
reductions for HF hospitalizations on statins were similar in
primary- and secondary-prevention trial participants, the absolute
risk reduction was considerably greater in secondary-prevention
participants whose HF event rates were substantially higher.
Pooled results for HF hospitalizations were previously available
from four dose-comparison statin trials (n ¼ 27 546) in participants
with established coronary heart disease, some of whom had HF at
baseline. These results published in 2006, which included HF
events within 30 days of MI, showed a 27% reduction in this end-
point.12 Of the previously published HF data from trials comparing
statins to placebo or standard care, only the Heart Protection
Study (HPS) demonstrated a reduction in any major HF event,
namely a borderline significant reduction of 14% in the composite
outcome of HF death and non-fatal HF hospitalization on simvastatin
compared with placebo [354 vs. 405 first events, RR 0.86 (95% CI
0.75–1.00)].4 In HPS, there were also trends towards reductions in
both HF death and non-fatal hospitalizations, respectively.4,33
However, other trials had found no such benefit, underlining the
need for a comprehensive synthesis of trial data.
Notably, we found that the benefit of statin therapy for HF out-
comes appeared similar regardless of whether an antecedent MI
occurred or not. For example, the number of participants requiring
hospitalization for non-fatal HF without a preceding within-trial MI
was significantly reduced by statins, to a similar extent as that
observed for participants with an earlier within-trial MI. A second
notable findingwas that the proportionof participants experiencing
HF events was dominated by thosewithout an earlier within-trial MI.
Indeed, 85–90% of HF events were not preceded by a documen-
ted within-trial MI. There are various potential explanations for
Figure 2 Continued
Figure 3 Funnel plot for non-fatal heart failure hospitalization.
Egger test P ¼ 0.74.
D. Preiss et al.1542
these two observations. With respect to the issue of preceding MI,
both the requirement for potential events to fulfil adjudication
requirements and the historical nature of the trials may have
resulted in an underestimation of the numbers of within-trial MIs.
Events that did not have complete documentation and the use of in-
sensitive biomarkers may have led to this. It is also recognized that
myocardial ischaemia, as well as MI, may result in reduced left ven-
tricular systolic function and, in patients with pre-existing systolic
dysfunction (which many participants in the present trials may
have had), precipitate HF. For example, in the Studies of Left Ven-
tricular Dysfunction trials, episodes of unstable angina led to a
60% increase in risk of subsequent HF hospitalization.34 Even myo-
cardial ischaemia that is not acutely symptomatic, or symptomatic at
all, may lead to left ventricular diastolic and systolic dysfunction
(manifest in the most extreme cases as ‘hibernating myocardium’).
Statins reduce symptomatic myocardial ischaemia and may also
reduce asymptomatic episodes.35 An alternative and more contro-
versial explanation is that statins may not only reduce the risk of
developing HF by preventing ischaemic events but also by unrecog-
nized pleiotropic mechanisms unlinked to LDL-cholesterol reduc-
tion, such as anti-inflammatory effects.36
The HF benefit of statin therapy is likely to be underestimated in
our analysis to some extent. Our analysis was limited to hospitaliza-
tion and excluded milder episodes where hospitalization was not
required. Importantly, the development of HF often leads to
repeated hospital admissions1 but our analysis was limited to the
risk of experiencing a first event and not recurrent events. The dur-
ation of follow-up (4.3 years)may also have been too short to showa
greaterbenefit. Forexample, theWestof ScotlandCoronaryPreven-
tion Study recently published data showing that, during extended
follow-up of 15 years, HF hospitalization was reduced by 43% in pra-
vastatin recipients compared with placebo recipients37 even though
noHF benefit was observed in the initial 5 year randomized trial.We
decided a priori to exclude HF events within 30 days after MI for
reasons described above. Data from the PROVE-IT TIMI 22 study,
in which participants were randomized to intensive or moderate
dose statin very soon after a coronary event, suggest that this was a
reasonable approach.12 In that trial, the effect of intensive statin
therapy on risk of hospitalization for HF was very similar regardless
of whether HF events in the first 30 days of randomization were
included or not [hazard ratios (HRs) 0.53 and 0.55, respectively],
though the effect size appeared markedly larger than observed in
the present analysis.
Our analysiswas designed to investigate the effect of statin therapy
on the development of HF and so could not address statins’ potential
effect on repeat HF hospitalization in those with existing HF.
However, the effect size we observed with statins was similar to
that observed in the CORONA trial which compared rosuvastatin
to placebo in patients with established systolic HF [5011 participants
of whom1291were hospitalized (2408 events) for HF, HR 0.91, 95%
CI 0.82–1.02]. In CORONA, statin therapy significantly reduced
both the risk of repeat HF admissions and the overall number of
admissions.38
Strengths of this meta-analysis include the following: first, it repre-
sents the largest systematic analysis evaluating the effect of statin
therapy on HF events with over 132 000 participants and over 570
000 patient-years of follow-up for the main analyses. This provided
power to detect potentially modest effects. Second, unpublished
datawere collected allowing us to provide information on homogen-
ous HF endpoints, as far as possible. And third, access to trial data
allowed harmonization of data and assessment of relevant subgroup
and sensitivity analyses. Potential weaknesses include the following:
first, the analyses were conducted with summary-level data, not
with individual participant data, and we combined trial-specific RRs
because not all trials could provideHRs for the outcomes of interest.
Second, HF outcomes were not pre-specified in many trials which
may have affected the quality of the data available for post hoc analysis,
and it was not possible to use a uniform definition for HF events due
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Effect of statin therapy on heart failure events according to the presence or absence of a previous within-trial
myocardial infarction
Number of trials First events/n on statin, first events/n
on control therapy
Risk ratio (95% CI) I2 (%)
Non-fatal heart failure hospitalizationa
First non-fatal hospitalization 17 1344/66 238, 1498/66 300 0.90 (0.84–0.97) 0
No MI preceding first non-fatal hospitalization 15 1096/63 357, 1211/63 452 0.91 (0.84–0.98) 0
MI preceding first non-fatal hospitalization 15 119/63 357, 137/63 452 0.87 (0.68–1.11) 0
Heart failure deatha
Death 14 213/57 734, 220/57 836 0.97 (0.80–1.17) 0
No MI preceding death 13 178/56 934, 181/57 036 0.98 (0.80–1.21) 0
MI preceding death 7 33/33 124, 35/33 232 0.95 (0.59–1.51) 0
Heart failure composite outcome (death or non-fatal hospitalization)a
First composite outcome 14 1234/57 734, 1344/57 836 0.92 (0.85–0.99) 0
No MI preceding first composite outcome 13 1093/56 934, 1170/57 036 0.94 (0.86–1.01) 0
MI preceding first composite outcome 12 128/48 033, 149/48 135 0.86 (0.68–1.09) 0
aAll HF events occurring ,30 days after within-trial MI excluded from analysis.
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to the nature of the data; however, limited heterogeneity for all the
analyses provides some confidence that any such variation did not
introduce systematic bias. Third, data were missing for some of the
HF endpoints and not all major statin trials could be included.
Fourth, we were unable to conduct a formal statistical comparison
of the HF risks of participants who did and did not experience a
within-trial MI prior to developing HF, but the large degree of
overlap for these respective results strongly suggests that there
was no difference between them. Fifth, we did not have access to
data regarding the likely aetiology ofHF though, based on the charac-
teristics of the trial participants, relatively feware likely to have devel-
oped preserved ejection HF. Sixth, we were unable to compare
outcomes in men and women.
In conclusion, our meta-analysis of data from major trials demon-
strated that statin therapy modestly reduced the risk of non-fatal HF
hospitalization and thecompositeoutcomeofHFdeathandnon-fatal
hospitalization over 4.3 years.
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